Rheumatoid arthritis (RA) is the most common auto-immune arthritis with a prevalence between 0.5 - 2.5%. It is associated with substantial morbidity, mortality, and cost. Disease modifying anti-rheumatic drugs (DMARDs) reduce inflammation through a variety of mechanisms, improving short and long-term outcomes in RA. While there are a variety of drug-related toxicities, DMARDs are now accepted as standard of care for the medical management of RA, being recommended by the National Committee on Quality Assurance, the American College of Rheumatology (ACR), and the European League Against Rheumatism. Despite the recognized benefits of DMARDs, several published studies from the US, Canada, and Europe have found that 25-50% of patients diagnosed with RA do not use DMARDs, indicating sub-optimal care. There seem to be two major factors driving DMARD non-use: lack of access to expert rheumatic disease care and patient preferences. Access to rheumatologists is an acknowledged problem based on a report of the ACR finding that the aging US population will contribute to a 50% shortage of rheumatologists by 2025. It is very unlikely that rheumatology training programs can make up the deficit, suggesting that primary care providers (PCPs) will need to increase their familiarity with managing rheumatologic conditions, including RA. This trend coincides with the current push for primary care redesign, allowing for more comprehensive and collaborative management of diseases sometimes managed by specialists. An improved system for co-management between PCPs and rheumatologists around diseases like RA is needed.
The first aim of this project, a 2x2 factorial randomized controlled trial, will test two different interventions. One will attempt to forge new collaborative care relationships between PCPs and rheumatologists, within the context of managing RA. The second will focus on patients and their preferences regarding RA treatment. Like other medications, patients express concerns about DMARD toxicities and how to balance risks and benefits. Addressing such issues appears to improve treatment compliance in other conditions and may help reduce DMARD non-use. We will attempt to address these issues through a telephonic health education program.
The second aim will examine the economic implications of the intervention. We will use simulation models to calculate the long-term implications of the interventions tested in the aim one.
This work is relevant because of the prevalence of RA, its associated morbidity and mortality, and the need to improve collaborative care. The lessons learned in the proposed research will inform system redesign in rheumatology as well as across the health care system.
|Zak, Agnes; Corrigan, Cassandra; Yu, Zhi et al. (2018) Barriers to treatment adjustment within a treat to target strategy in rheumatoid arthritis: a secondary analysis of the TRACTION trial. Rheumatology (Oxford) 57:1933-1937|
|von Heideken, Johan; Iversen, Maura D; Gerdhem, Paul (2018) Rapidly increasing incidence in scoliosis surgery over 14 years in a nationwide sample. Eur Spine J 27:286-292|
|MacFarlane, Lindsey A; Yang, Heidi; Collins, Jamie E et al. (2018) Relationship between patient-reported swelling and MRI-defined effusion-synovitis in patients with meniscus tears and knee osteoarthritis. Arthritis Care Res (Hoboken) :|
|Sparks, Jeffrey A; Lin, Tzu-Chieh; Camargo Jr, Carlos A et al. (2018) Rheumatoid arthritis and risk of chronic obstructive pulmonary disease or asthma among women: A marginal structural model analysis in the Nurses' Health Study. Semin Arthritis Rheum 47:639-648|
|Kreps, David J; Halperin, Florencia; Desai, Sonali P et al. (2018) Association of weight loss with improved disease activity in patients with rheumatoid arthritis: A retrospective analysis using electronic medical record data. Int J Clin Rheumtol 13:1-10|
|Solomon, Daniel H; Lu, Bing; Yu, Zhi et al. (2018) Benefits and Sustainability of a Learning Collaborative for Implementation of Treat-to-Target in Rheumatoid Arthritis: Results of a Cluster-Randomized Controlled Phase II Clinical Trial. Arthritis Care Res (Hoboken) 70:1551-1556|
|Prado, Maria G; Iversen, Maura D; Yu, Zhi et al. (2018) Effectiveness of a Web-Based Personalized Rheumatoid Arthritis Risk Tool With or Without a Health Educator for Knowledge of Rheumatoid Arthritis Risk Factors. Arthritis Care Res (Hoboken) 70:1421-1430|
|Lee, Moa P; Lii, Joyce; Jin, Yinzhu et al. (2018) Patterns of Systemic Treatment for Psoriatic Arthritis in the US: 2004-2015. Arthritis Care Res (Hoboken) 70:791-796|
|Barbhaiya, Medha; Tedeschi, Sara K; Lu, Bing et al. (2018) Cigarette smoking and the risk of systemic lupus erythematosus, overall and by anti-double stranded DNA antibody subtype, in the Nurses' Health Study cohorts. Ann Rheum Dis 77:196-202|
|Sparks, Jeffrey A; Iversen, Maura D; Yu, Zhi et al. (2018) Disclosure of Personalized Rheumatoid Arthritis Risk Using Genetics, Biomarkers, and Lifestyle Factors to Motivate Health Behavior Improvements: A Randomized Controlled Trial. Arthritis Care Res (Hoboken) 70:823-833|
Showing the most recent 10 out of 444 publications